

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

**INSIDE INFORMATION
PROPOSED TRANSFER OF LISTING
FROM THE GROWTH ENTERPRISE MARKET TO THE MAIN BOARD OF
THE STOCK EXCHANGE OF HONG KONG LIMITED
RELATED TO TONG REN TANG CHINESE MEDICINE**

This announcement is made by Tong Ren Tang Technologies Co. Ltd. (the "**Company**") pursuant to Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Law of Hong Kong) and Rule 13.09 of the Rules Governing the Main Board Listing of Securities (the "**Main Board Listing Rules**") on The Stock Exchange of Hong Kong Limited " (the "**Stock Exchange**").

The subsidiary of the Company, Beijing Tong Ren Tang Chinese Medicine Company Limited ("**Tong Ren Tang Chinese Medicine**"), has submitted a formal application to the Stock Exchange on 1 February 2018 (after trading hours) for the proposed transfer of listing pursuant to Chapter 9A of the Main Board Listing Rules and the relevant provisions of the GEM Listing Rules (the "**Proposed Transfer**"). The Proposed Transfer will not involve the issue of any new shares of the Company and Tong Ren Tang Chinese Medicine. Please refer to the announcement made by Tong Ren Tang Chinese Medicine dated on 1 February 2018 for details of the Proposed Transfer.

The Board would like to emphasize that the definitive timetable for the Proposed Transfer has yet to be finalised. The Company and Tong Ren Tang Chinese Medicine will make further announcements in relation to the progress of the Proposed Transfer as and when appropriate.

There is no assurance that approval will be obtained from the Stock Exchange for the Proposed Transfer. Shareholders and potential investors should be aware that the Proposed Transfer is subject to, among others, the conditions of the Proposed Transfer being fulfilled and thus the Proposed Transfer may become effective. Accordingly, Tong Ren Tang Chinese Medicine may or may not proceed with the Proposed Transfer. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Gao Zhen Kun
Chairman of the Board

Beijing, the PRC
1 February 2018

As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gu Hai Ou, Mr. Rao Zu Hai, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.